TY - JOUR
T1 - Bis-choline tetrathiomolybdate prevents copper-induced blood-brain barrier damage
AU - Borchard, Sabine
AU - Raschke, Stefanie
AU - Zak, Krzysztof M.
AU - Eberhagen, Carola
AU - Einer, Claudia
AU - Weber, Elisabeth
AU - Müller, Sandra M.
AU - Michalke, Bernhard
AU - Lichtmannegger, Josef
AU - Wieser, Albrecht
AU - Rieder, Tamara
AU - Popowicz, Grzegorz M.
AU - Adamski, Jerzy
AU - Klingenspor, Martin
AU - Coles, Andrew H.
AU - Viana, Ruth
AU - Vendelbo, Mikkel H.
AU - Sandahl, Thomas D.
AU - Schwerdtle, Tanja
AU - Plitz, Thomas
AU - Zischka, Hans
N1 - Publisher Copyright:
© 2021 Borchard et al.
PY - 2021/3
Y1 - 2021/3
N2 - In Wilson disease, excessive copper accumulates in patients' livers and may, upon serum leakage, severely affect the brain according to current viewpoints. Present remedies aim at avoiding copper toxicity by chelation, for example, by D-penicillamine (DPA) or bis-choline tetrathiomolybdate (ALXN1840), the latter with a very high copper affinity. Hence, ALXN1840 may potentially avoid neurological deterioration that frequently occurs upon DPA treatment. As the etiology of such worsening is unclear, we reasoned that copper loosely bound to albumin, that is, mimicking a potential liver copper leakage into blood, may damage cells that constitute the blood-brain barrier, which was found to be the case in an in vitro model using primary porcine brain capillary endothelial cells. Such blood-brain barrier damage was avoided by ALXN1840, plausibly due to firm protein embedding of the chelator bound copper, but not by DPA. Mitochondrial protection was observed, a prerequisite for blood-brain barrier integrity. Thus, high-affinity copper chelators may minimize such deterioration in the treatment of neurologic Wilson disease.
AB - In Wilson disease, excessive copper accumulates in patients' livers and may, upon serum leakage, severely affect the brain according to current viewpoints. Present remedies aim at avoiding copper toxicity by chelation, for example, by D-penicillamine (DPA) or bis-choline tetrathiomolybdate (ALXN1840), the latter with a very high copper affinity. Hence, ALXN1840 may potentially avoid neurological deterioration that frequently occurs upon DPA treatment. As the etiology of such worsening is unclear, we reasoned that copper loosely bound to albumin, that is, mimicking a potential liver copper leakage into blood, may damage cells that constitute the blood-brain barrier, which was found to be the case in an in vitro model using primary porcine brain capillary endothelial cells. Such blood-brain barrier damage was avoided by ALXN1840, plausibly due to firm protein embedding of the chelator bound copper, but not by DPA. Mitochondrial protection was observed, a prerequisite for blood-brain barrier integrity. Thus, high-affinity copper chelators may minimize such deterioration in the treatment of neurologic Wilson disease.
UR - http://www.scopus.com/inward/record.url?scp=85122124702&partnerID=8YFLogxK
U2 - 10.26508/lsa.202101164
DO - 10.26508/lsa.202101164
M3 - Article
C2 - 34857647
AN - SCOPUS:85122124702
SN - 2575-1077
VL - 5
JO - Life Science Alliance
JF - Life Science Alliance
IS - 3
M1 - 202101164
ER -